Research Paper Volume 11, Issue 13 pp 4338—4353
Targeting HMGB1 by ethyl pyruvate ameliorates systemic lupus erythematosus and reverses the senescent phenotype of bone marrow-mesenchymal stem cells
Figure 4. (A, B) The expression of TLR4, p-IRAK1, p-p65 and IκBa from SLE compared with normal group were determined by western blot analysis. GAPDH was used as the internal control. (C, D) MSCs were depleted of TLR4 by RNAi. The second one was chosen as the best siRNA by western blotting. (E, F) MSCs were fixed and stained for SA-β-gal. The number of SA-β-gal-positive cells obviously decreased among treated SLE MSCs in comparison with untreated group. (G) MSCs were stained by fluorescein isothiocyanate-conjugated phalloidin. The disordered distribution of F-actin was reversed in siTLR4-treated MSCs. (Bar represents mean ± SD,*P < 0.05 compared with the normal group, #P < 0.05 compared with the SLE group,) (NOR=normal group, SLE=systemic lupus erythematosus patients group).